Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2025 Aug;31(8):480-493.
doi: 10.1016/j.jtct.2025.05.001. Epub 2025 May 21.

American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy

Eleftheria Kampouri  1 , Guy Handley  2 , Tuan L Phan  3 , Yeon Joo Lee  4 , Ryan Shaw  5 , Paul A Carpenter  6 , Sanjeet S Dadwal  7 , Roy F Chemaly  2 , Genovefa A Papanicolaou  4 , Masao Ogata  8 , Michael Boeckh  9 , Danielle M Zerr  10 , Joshua A Hill  11
Affiliations
Practice Guideline

American Society for Transplantation and Cellular Therapy Series #9: Management of Human Herpesvirus 6B After Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T-Cell Therapy

Eleftheria Kampouri et al. Transplant Cell Ther. 2025 Aug.

Abstract

The Practice Guidelines Committee and the Transplant Infectious Disease Special Interest Group of the American Society for Transplantation and Cellular Therapy developed guidelines focusing on human herpesvirus 6B (HHV-6B). A compendium-style approach was used to address a series of standalone frequently asked questions (FAQs), supported by tables and figures to spotlight key concepts. Adult and pediatric infectious disease and hematopoietic cell transplantation (HCT) content experts developed these FAQs and finalized recommendations after consensus was reached. This ninth topic in the series focuses on the relevant risk factors, diagnostic considerations, prophylaxis, and treatment approaches relevant to HHV-6B infections after HCT and chimeric antigen receptor-T-cell therapy.

Keywords: Allogeneic hematopoietic cell transplant; CAR-T-cell therapy; Encephalitis; HHV-6; Inherited chromosomally integrated HHV-6.

PubMed Disclaimer

Conflict of interest statement

E.K. received consulting fees from Merck and honoraria from Takeda and Merck.

Y.J.L. reports institutional reimbursement for subjects enrolled on clinical trials from AiCuris and Scynexis. She also reports a research grant paid to her institution from MSD.

S.S.D. received research funding paid to institution from Allovir, Ansun Biopharma, Pfizer, Basilea, F2G, Symbio, Merck, received consulting fees and/or participated in advisory boards from Merck, Takeda, Allovir, Karius, Basilea, Aseptiscope Inc. and honoraria (speakers bureau) from Karius, Takeda, Astellas and Merck.

R.F.C. received research grants paid to his institution from the NIH/NCI (RO1), Aicuris, Ansun Biopharma, Genentech, Karius, Symbio, Merck & Co., Oxford Immunotec, Pulmotect, Freestyle, Takeda, and Eurofins Viracor and honoraria/consulting fees from Ansun Biopharma, Merck & Co./MSD, Oxford Immunotec, Tether, Takeda, Shionogi, Assembly Bio, IntegerBio, Symbio, InflaRx, Gilead, Pfizer, Moderna, Invyvid, Eurofins Viracor, and Karius.

M.O. received consulting fees from Symbio.

M.J.B. has served as consultant for Merck, Takeda, Symbio, AssemblyBio, Allovir and Moderna; has received research funding from Merck and Moderna; has served as consultant and had option to acquire stock for EvrysBio.

D.M.Z. received research funding paid to her institution from Merck and consulting fees from AlloVir

J.A.H. received research grants paid to his institution from Gilead, Takeda, Geovax, and Sanofi and honoraria/consulting fees from Moderna, Allovir, Gilead, Takeda, CSL Behring, Karius, Geovax, Symbio, and Sanofi.

All other authors declare no conflicts of interest related to this work.

Similar articles

See all similar articles

References

    1. Zerr DM, Meier AS, Selke SS, et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352(8):768–776. doi: 10.1056/NEJMoa042207 - DOI - PubMed
    1. Hill JA, Koo S, Guzman Suarez BB, et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012;18(11):1638–1648. doi: 10.1016/j.bbmt.2012.04.016 - DOI - PMC - PubMed
    1. Zerr DM, Boeckh M, Delaney C, et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1700–1708. doi: 10.1016/j.bbmt.2012.05.012 - DOI - PMC - PubMed
    1. Ogata M, Oshima K, Ikebe T, et al. Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(11):1563–1570. doi: 10.1038/bmt.2017.175 - DOI - PubMed
    1. Bates M, Monze M, Bima H, et al. Predominant human herpesvirus 6 variant A infant infections in an HIV-1 endemic region of Sub-Saharan Africa. J Med Virol. 2009;81(5):779–789. doi: 10.1002/JMV.21455 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources